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depressive symptoms
Abstract

Orbitofrontal cortex (OFC) sulcogyral patterns are stable morphological variations established early in life.
They consist of three distinct pattern types, with Type III in particular being associated with poor regulatory
control (e.g., high sensation seeking and negative emotionality, low constraint), which may confer risk for
earlier onset of cannabis (CB) use and greater use in later life. The OFC sulcogyral pattern may therefore be a
stable trait marker in understanding individual differences in substance-use vulnerability and associated
affective disturbances in users. In a large multisite cross-sectional study, we compared OFC pattern type
distribution between 128 healthy controls (HC) and 146 CB users. Within users (n = 140), we explored the
association between OFC pattern type and CB use level, and subsequently if level of CB use informed by
OFC pattern type may mediate disturbances in affective tone, as indexed by depressive symptoms. While
OFC pattern distribution did not distinguish between HC and CB groups, it informed greater lifetime use
within users. Specifically, CB users with pattern Type III in the right OFC tended to use more CB over their
lifetime, than did CB users with pattern Type I or II. Greater lifetime CB use was subsequently associated with
higher depressive symptoms, such that it mediated an indirect association between right OFC pattern Type
III and higher depressive symptoms. The present study provides evidence for neurobiological differences,
specifically sulcogyral pattern of the OFC, to modulate level of CB use, which may subsequently influence the
expression of depressive symptoms.
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Abstract
Orbitofrontal cortex (OFC) sulcogyral patterns are stable morphological variations established
early in life. They consist of three distinct pattern types, with Type III in particular being
associated with poor regulatory control (e.g., high sensation seeking and negative
emotionality, low constraint), which may confer risk for earlier onset of cannabis (CB) use and
greater use in later life. The OFC sulcogyral pattern may therefore be a stable trait marker in
understanding individual differences in substance-use vulnerability and associated affective
disturbances in users. In a large multisite cross-sectional study, we compared OFC pattern
type distribution between 128 healthy controls (HC) and 146 CB users. Within users (n =
140), we explored the association between OFC pattern type and CB use level, and
subsequently if level of CB use informed by OFC pattern type may mediate disturbances in
affective tone, as indexed by depressive symptoms. While OFC pattern distribution did not
distinguish between HC and CB groups, it informed greater lifetime use within users.
Specifically, CB users with pattern Type III in the right OFC tended to use more CB over their
lifetime, than did CB users with pattern Type I or II. Greater lifetime CB use was subsequently
associated with higher depressive symptoms, such that it mediated an indirect association
between right OFC pattern Type III and higher depressive symptoms. The present study
provides evidence for neurobiological differences, specifically sulcogyral pattern of the OFC,
to modulate level of CB use, which may subsequently influence the expression of depressive
symptoms.

Keywords: Dependence, cannabis, orbitofrontal cortex, sulcogyral pattern, MRI

Abbreviations:
OFC = orbitofrontal cortex; MOS = medial orbitofrontal sulcus; LOS = lateral orbitofrontal
sulcus; CB = cannabis; HC = healthy controls
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Introduction
Cannabis (CB) is a widely used psychoactive drug with a global estimate of 182 million users
(United Nations Office on Drugs and Crime, 2015). Along with the high level of CB use across
the world, there is a rising toll of treatment demand for CB use and its disorders (European
Monitoring Centre for Drugs and Drug Addiction, 2016; United Nations Office on Drugs and
Crime, 2015). Heavy CB use has been linked to affective disturbances such as depressive
disorders (Degenhardt et al., 2003; Lev-Ran et al., 2014). Efforts to uncover the neural
correlates of CB use have demonstrated morphological alterations across various brain
regions including the hippocampus and the prefrontal cortex (Lorenzetti et al., 2016; Yücel et
al., 2016). While neural abnormalities have often been interpreted as a consequence of CB
use (Ashtari et al., 2011; Cousijn et al., 2012; Matochik et al., 2005; Yücel et al., 2008),
premorbid structural differences may similarly confer vulnerability to develop heavier patterns
of CB use (Jacobus et al., 2016; Pagliaccio et al., 2015) or affective disturbances (Amico et
al., 2011). The understanding of such premorbid differences may inform knowledge on
individual differences in substance use vulnerability, and the associated affective
disturbances in users.

It remains unclear whether (and which) neurobiological alterations predate cannabis
use onset. Asides from prospective studies, this issue can be addressed via assessing
neuroanatomy that is defined early in life and relatively stable to postnatal environmental
factors such as substance use. One such medium is the specific pattern of gyrification of the
brain (White et al., 2010). Gyrification is the pattern of surface folding of the brain (White et
al., 2010) that develops as early as 11 to 16 weeks gestation, and remains relatively stable
from birth (Armstrong et al., 1995; Zilles et al., 1997). Importantly, early cortical folding
forming particular sulcogyral patterns may reflect underlying connectivity or disrupted
connectivity of the brain (Toro and Burnod, 2005; White et al., 2010). This provides a means
for structure to inform function and behaviour, particularly in regions strongly implicated in
substance use, such as the orbitofrontal cortex (OFC). Various studies have demonstrated
reduced OFC volume (Battistella et al., 2014; Churchwell et al., 2010) and altered OFC
function (functional connectivity in reward and inhibitory circuitry including the OFC) (Filbey
and Dunlop, 2014; Filbey and Yezhuvath, 2013) in CB users. Pre-existing OFC morphological
differences may also inform risk for later substance (i.e. alcohol, CB) use (Cheetham et al.,
2011; Kühn et al., 2015). These studies suggest OFC morphology may reflect vulnerabilities
that inform future substance use behaviour.

The sulcogyral pattern of the OFC in particular, is a viable trait marker to glean stable
prenatal differences that may inform substance use behaviour. The OFC sulcogyral pattern
has been categorised by Chiavaras and Petrides (2000), based on the continuity/discontinuity
of the medial orbitofrontal sulcus (MOS) and the lateral orbitofrontal sulcus (LOS), into three
basic types (Type I – discontinuity of the MOS; Type II – continuity of both the MOS and the

3

LOS; Type III – discontinuity of the LOS; Fig. 1). In a normative population, the distribution of
the OFC sulcogyral pattern is skewed, with a predominance of Type I and an
underrepresentation of Type III (Chiavaras and Petrides, 2000).

Fig. 1 Examples of the three different orbitofrontal (OFC) sulcogyral pattern types, as traced
on the coronal plane, and viewed on the transverse plane. Type I: rostral and caudal regions
of the medial orbitofrontal sulci (MOSr and MOSc, red) are discontinuous, while the lateral
orbitofrontal sulcus (LOS, purple) is continuous; Type II: both the MOS and LOS are
continuous; Type III: the rostral and caudal regions of the MOSr and MOSc, as well as LOSr
and LOSc are discontinuous. Also depicted are the intermediate orbital sulci (green and blue),
and the transvers orbital sulci (TOS, yellow). Reproduced with permission from
Bartholomeusz et al. (2013).

However, altered pattern distribution has been associated with specific personality
traits and presence of psychopathologies. In adolescents, a Type III pattern has been linked
to greater ‘surgency’ (representing sensation-seeking and extraversion traits, and low levels
of fear or shyness) (Whittle et al., 2014). Similarly in patients with schizophrenia, Type III
pattern has been associated with temperaments (low ‘constraint’ and high ‘negative
emotionality’) indicative of impulsivity, stress reaction, and proneness to anxiety and
aggression (Nakamura et al., 2007), as well as poorer functioning (i.e. greater positive
symptoms and lower socioeconomic status (Nakamura et al., 2007; Uehara-Aoyama et al.,
2011)). Patients with schizophrenia also show an altered proportion of sulcogyral pattern
relative to controls (decreased proportion of Type I, and increased proportion of Type II and
III) (Bartholomeusz et al., 2013; Chakirova et al., 2010; Cropley et al., 2015; Isomura et al.,
2017; Nakamura et al., 2008, 2007; Nishikawa et al., 2015; Takahashi et al., 2015; UeharaAoyama et al., 2011). Overall, in both healthy and schizophrenia patient populations, Type III
pattern is linked to personality traits reflecting poor regulatory control. Such traits may in turn
confer risk for substance use, having been demonstrated to predict an earlier onset of
substance use disorder, greater dependence, and greater lifetime CB use (Creemers et al.,
2010; Elkins et al., 2006; Krueger, 1999). Thus pre-existing OFC neuroanatomy, by reflecting
underlying behavioural regulatory function, may be able to inform risk for later substance use.
While the OFC volume has been demonstrated to predict CB use initiation in adolescents
(Cheetham et al., 2011), no study has yet explored the OFC sulcogyral pattern in relation to
CB use.
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Regulatory deficits associated with altered OFC function may not only contribute to
greater substance use, but also confer risk for affective disturbances (Diekhof et al., 2008;
Drevets, 2007; Klimes-Dougan and Garber, 2016; Wagner et al., 2013a). Consistently,
reduced OFC volume (Bremner et al., 2002; Lacerda et al., 2004) and altered functional
connectivity between the OFC, dorsolateral prefrontal and anterior cingulate cortices (Frodl et
al., 2010) have been observed in patients with depression. Importantly, regular CB use has
also been associated with the emergence of affective disturbances including higher
depressive symptoms (Crane et al., 2015) and an increased risk of developing depression
(Lev-Ran et al., 2014). It is proposed that impaired OFC regulatory function and
neuroanatomy underlies the concurrent development of CB use and depressive symptoms
(Otten et al., 2010; Volkow and Fowler, 2000), via intensifying the strength of impulse and
emotions (Beer et al., 2006; Wagner et al., 2013b). If specific OFC sulcogyral pattern types
reflects distinct regulatory functions (Whittle et al., 2014), then these pattern type may inform
later level of CB use and affective disturbances in CB users.

In this study, we (i) compared the distribution of OFC pattern type between healthy
controls (HC) and CB users to discern neural differences that may inform CB use; (ii)
explored the association between OFC pattern type and CB use levels (i.e. three distinct
measures including age of onset of regular use, current monthly use, and cumulative lifetime
use) in CB users, to understand if potentially pre-existing OFC pattern type may inform later
levels of CB use. We additionally (iii) explored whether higher levels of CB use will mediate a
possible link between OFC pattern type and greater depressive symptoms, as guided by any
significant association between OFC pattern type and specific CB use variables from analysis
(ii). We hypothesised (i) OFC pattern distribution to be altered in CB users compared to HC;
(ii) Type III pattern – linked to traits indicative of poor regulatory control – will be associated
with higher CB use levels; and that (iii) CB users with Type III pattern would have greater
current depressive symptoms, and that this relationship would be mediated by greater CB use
level.

Method
Participants
We examined an aggregated sample of 128 HC and 146 regular CB users aged 17 to 55
years, the data of which have been previously collected across four research sites including
the University of Amsterdam (Amsterdam, N=76) (Cousijn et al., 2012), University of
Barcelona (Barcelona, N=60) (Batalla et al., 2013), University of Wollongong (Wollongong,
N=34) (Solowij et al., 2013), and Monash University (Melbourne, N=104) (Yücel et al., 2016).
Informed written consent was obtained from all participants. All regular CB users had used
CB at least two smoking days per month for a minimum of two months, and the majority of
users smoked almost daily for a substantial period of time (duration of regular use, Mdn = 6
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years, range = 0.5 – 38 years). Meanwhile, all HCs had minimal CB exposure (used less than
50 times in their life, and did not use in last month). Exclusion criteria were: any history of
chronic medical illness or neurological condition; use of psychoactive medications; any
lifetime Axis I disorder according to the Diagnostic and Statistical Manual for Mental
Disorders-Fourth Edition (other than nicotine use disorder, or cannabis use disorder for
cannabis users); general MRI contraindications; regular use of other drugs (>50 times in the
past 10 years) apart from cannabis, alcohol, and nicotine; and IQ<80.

Measures
Participants’ demographic, IQ level, depressive symptoms, and substance use levels
(alcohol, tobacco, CB) were separately collected from each site using differing measures. We
standardized these measures across sites. CB use levels measured include age of onset of
regular use (defined as at least twice/month for at least two months), current monthly use,
and cumulative lifetime use. CB users self-reported use in units familiar to them (e.g., joints,
bongs, grams smoked), and use was then converted to cones, a standardised unit for
comparison (e.g., 1 gram = 12 cones, and 1 paper joint = 3 cones; see standardised
guidelines provided at https://cannabissupport.com.au/media/1593/timeline-followback.pdf).

IQ was estimated using the Dutch version of the National Adult Reading Test (DART)
(Schmand et al., 1991) (Amsterdam); the vocabulary subscale of the Wechsler Adult
Intelligence Scale – Third Edition (WAIS-III) (Barcelona) (Wechsler, 1997); the National Adult
Reading Test (NART) (Wollongong) (Nelson, 1982); and the Wechsler Abbreviated Scale of
Intelligence (WASI) (Melbourne) (Wechsler, 1999). The vocabulary subscale score from the
Barcelona site was converted to an estimated full scale IQ by standardising to the mean and
standard deviation of the average IQ of CB and HC respectively of the three other sites.
Depressive symptoms were obtained using the Beck Depression Inventory (BDI)
(Amsterdam, Barcelona, Melbourne) (Beck et al., 1961) and Hamilton Depression Rating
Scale (HAMD) (Wollongong) (Hamilton, 1960). Depressive symptom scores from each site
were standardised, using previously reported population norms for each scale as the mean by
which obtained depressive symptom scores were converted to a z-score (Crawford et al.,
2011; Zimmerman et al., 2004).

Structural Image Processing
T1-weighted structural MR images were independently acquired at each imaging site.
Scanner details are documented in the Supplementary Table 1, and by the original research
groups (Batalla et al., 2013; Cousijn et al., 2012; Yücel et al., 2016, 2008). MR image were
preprocessed using FreeSurfer image analysis (http://surfer.nmr.mgh.harvard.edu/) version
5.3.0 to correct for intensity non-uniformity artifacts (Sled et al., 1998; Zheng et al., 2009).
The intensity of the subsequent MR images was then standardised between sites - based on
the average grey matter, white matter, and cerebrospinal fluid intensity from each site, using
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the FMRIB Software Library (FSL; http://www.fmrib.ox.ac.uk/fsl/), to ensure consistency
across sites for subsequent manual tracing. Finally, MR images were visually inspected and
reoriented along the anterior commissure-posterior commissure (AC-PC) plane only if they
deviated from the plane by more than 0.1 radian.

OFC sulcogyral pattern classification
The OFC sulcogyral pattern types were classified for each MR image using the visualisation
and analysis software Analyze 12.0 (AnalyzeDirect, Overland Park, KS), based on the
continuity/discontinuity of the MOS and LOS between the rostral and caudal regions
(Chiavaras and Petrides, 2000). In Type I, the MOS was disconnected while the LOS was
intact. In Type II, both the MOS and LOS were intact. For Type III, both the MOS and LOS
were disconnected. In rare cases where LOS was disconnected but MOS was intact (n = 27;
classified as Type IV in some papers (Chakirova et al., 2010)), we classified the OFC pattern
as Type III, in accordance with the method used by (Bartholomeusz et al., 2013).

All sulci appearing on the orbital surface were traced in the coronal plane slice-byslice, and identified on the transverse plane. A fissure was considered a sulcus if it was
visible in at least four coronal and four transverse slices. A sulcus was considered continuous
with another sulcus if they were clearly connected in at least three slices. OFC pattern
classification was performed by Y.C. while blinded to gender, group, and imaging site. Intraand inter-rater reliability (interclass correlation coefficient, ICC) performed by Y.C., C.F.B.,
and E.P.G., on 20 randomly selected brains from the Melbourne Neuropsychiatry Centre
(University of Melbourne, Department of Psychiatry) database, were 0.90 and 0.75
respectively. All ambiguous classifications identified in the current sample (i.e. 14% of the
total sample) were reviewed by C.F.B. and consensus reached. To further ensure Y.C.’s
classification validity, a subset of 20 randomly selected brains (5 from each imaging site) that
were not reviewed by C.B., from the current sample, were also reviewed by E.P.G.
Consensus between Y.C. and E.P.G. was high at a level of 92.5%.

Statistical Analyses
Group differences between HC and CB users for variables including age, IQ, depressive
symptoms, alcohol, and tobacco use were assessed using independent-samples t-test; while
group differences for gender were assessed via Pearson’s χ statistics. To ensure that OFC
2

pattern distribution was not related to imaging site, countries, or continents, we ran separate
Pearson’s χ statistics for HC and CB users, comparing left and right OFC pattern across
2

sites, and across continents. We also compared left and right OFC pattern distribution by age,
gender, IQ, depressive symptoms, alcohol and tobacco use to assess and rule out any
demographic confounder.
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To discern putative pre-existing neural differences in CB users relative to HC in OFC
sulcogyral pattern distribution (separately for right and left hemisphere) we ran χ statistics.
2

Subsequently to understand the link between OFC sulcogyral pattern and CB use levels in
CB users only, we performed a series of three separate ANCOVAs to explore whether OFC
pattern affected three distinct measures of CB use levels (i.e., age of onset of regular use,
current monthly use, and cumulative lifetime use). Fixed factors included left and right OFC
patterns, dependent variables included one of the three measures of CB use level, and the
remaining two measures of CB use levels were used as covariates. We corrected for multiple
comparisons (i.e. three comparisons corresponding to three CB use measures) using
Benjamini and Yekutieli’s modified false discovery rate (FDR) method (Benjamini and
Yekutieli, 2001).

Finally, to explore the role of higher CB use level as a mediator between specific
OFC pattern type and greater depressive symptoms, we ran post-hoc analyses with the
significant CB use variable emerging from the ANCOVA results, in a mediation model. CB
use level is adopted as a mediator between OFC pattern types (categorical factor) and
depressive symptoms. The mediation model was tested using the Hayes PROCESS macro
(2.16.2), instead of the causal step approach (wherein each path of the model is ascertained
separately), due to criticisms of the latter approach (Hayes, 2016, 2013, 2009). Indirect effect
was calculated using bias-corrected bootstrap confidence interval (CI) method, with 5,000
resamples.

Results
Demographics
Sample data and OFC pattern distribution of HC and CB users are presented in Table 1. HC
and CB users were matched by age, gender, and alcohol use level. CB users had a
significantly lower IQ (p < .001), greater depressive symptoms (p < .001), and used more
cigarettes per month (p < .001) than HC. Further sample characteristics by imaging site are
provided in Supplementary Table 2.

Table 1 Overview of Demographic, IQ, Substance Use Levels (Mean (SD)), and Orbitofrontal
Cortex (OFC) Pattern Distribution (n (%)) of Healthy Controls (HC) and Cannabis (CB) Users
HC

c

N = 128

CB

c

N

t/χ

2

p

N = 146

Age

26.25 (8.86)

28.41 (10.51)

274

1.84

.07

Gender (% M / F)

71.09/28.91

67.12/32.88

274

0.50

.51

109.26 (10.43)

103.58 (10.67)

270

-4.41

<.001**

IQ

a

Depressive Symptoms

b

-0.41 (0.65)

0.26 (1.19)

267

5.56

<.001**

Alcohol (StDr/mth)

c

19.71 (23.63)

24.55 (25.13)

264

1.61

.11

Tobacco (Cig/mth)

c

29.89 (96.49)

258.01 (236.04)

267

10.56

<.001**
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Cannabis Use
Onset Regular Use (years)

-

17.85 (3.37)

141

Current Use (cones/month)

-

339.59 (322.90)

143

Lifetime Use (cones)

-

58,164.51

144

(99,182.44)
c

Right OFC sulcogyral pattern, n (%)
Type I

63 (49)

69 (47)

Type II

21 (16)

31 (21)

Type III

44 (34)

46 (32)

Left OFC sulcogyral pattern, n (%)

a

Type I

64 (50)

70 (48)

Type II

25 (20)

27 (18)

Type III

39 (30)

49 (34)

1.06

.59

0.30

.86

Estimated IQ measured with the Dutch version of the National Adult Reading Test (DART; Amsterdam)

(Schmand et al., 1991), the vocabulary subscale of the Wechsler Adult Intelligence Scale – Third Edition
(WAIS-III; Barcelona) (Wechsler, 1997); the National Adult Reading Test (NART; Wollongong) (Nelson,
1982), and the Wechsler Abbreviated Scale of Intelligence (WASI; Melbourne) (Wechsler, 1999).
b

Depressive symptoms measured with the Beck Depression Inventory (BDI; Amsterdam, Barcelona,

Melbourne) (Beck et al., 1961) and Hamilton Depression Rating Scale (HAMD; Wollongong) (Hamilton,
1960); and subsequently standardized to a z-score based on reported population means (Crawford et
al., 2011; Zimmerman et al., 2004).
c

StDr/mth = standard drinks per month; Cig/mth = cigarettes smoked per month; OFC = orbitofrontal

cortex; HC = healthy controls; CB = cannabis users
**p<.001

Prior to the main analysis, χ tests within each of HC and CB groups, examined
2

across imaging sites, within and across continents, suggested no significant differences in
OFC pattern distribution associated with imaging site, and within or across continents
(Supplementary Table 3). Nor did OFC pattern distribution differ significantly by gender, IQ,
and demographic variables in the right and left hemispheres (Table 2). Therefore we did not
include any of these variables as factors in any further analyses.
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Table 2 Comparison of Differences in Orbitofrontal Cortex (OFC) Pattern Distribution in All Participants by Demographic, IQ, and Cannabis Use Levels
Right Hemisphere

Type I

Type II

Type III

N = 132

N = 52

N = 90

N

F/χ2

p

Age

26.90 (9.86)

26.34 (8.48)

28.75 (10.40)

274

1.41

.25

Gender (% M / F)

69.70/30.30

69.20/30.80

67.80/32.20

274

0.09

.95

106.58 (11.74)

104.91 (8.85)

106.52 (10.75)

270

0.54

.58

IQ

a

Depressive Symptoms

b

-0.04 (1.07)

-0.11 (0.84)

-0.02 (1.09)

267

0.16

.85

Alcohol (StDr/mth)

c

22.88 (26.32)

22.72 (25.26)

21.14 (21.22)

264

0.29

.87

Tobacco (Cig/mth)

c

161.53 (221.55)

127.19 (207.63)

172.48 (236.13)

267

0.47

.63

N

F

p

Cannabis Use

d

Type I

Type II

Type III

N = 67

N = 28

N = 45

Onset Regular Use (years)

17.73 (3.09)

18.16 (4.05)

17.84 (3.41)

140

0.15

.86

Current Use (cones/month)

371.73 (402.87)

280.48 (216.76)

327.46 (243.54)

140

2.31

.10

Lifetime Use (cones)

49,392.85 (70,590.47)

38,737.82 (45,936.98)

73,538.91 (89,776.01)

140

3.91

.02*

N

F/χ2

p

Left Hemisphere

Type I

Type II

Type III

N = 134

N = 52

N = 88

Age

27.05 (9.59)

25.97 (8.71)

28.78 (10.66)

274

1.61

.20

Gender (% M / F)

64.90/35.10

73.10/26.90

72.70/27.30

274

2.02

.37

105.62 (11.81)

105.94 (10.32)

107.39 (9.82)

270

0.79

.45

IQ

a

Depressive Symptoms

b

-0.08 (0.97)

-0.05 (1.08)

-0.01 (1.11)

267

0.16

.86

Alcohol (StDr/mth)

c

22.23 (23.38)

24.44 (27.41)

21.14 (24.61)

264

0.29

.75

Tobacco (Cig/mth)

c

149.63 (207.43)

138.73 (208.58)

160.74 (235.55)

267

0.18

.83

N

F

p

Cannabis Use

d

Type I

Type II

Type III
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N = 67

a

N = 26

N = 47

Onset Regular Use (years)

17.78 (3.50)

18.14 (2.84)

17.80 (3.55)

140

0.11

.90

Current Use (cones/month)

323.48 (244.38)

319.04 (345.98)

372.92 (410.44)

140

0.09

.92

Lifetime Use (cones)

53,420.97 (74,265.86)

40,971.54 (54,277.86)

65,080.13 (83,109.55)

140

0.67

.51

Estimated IQ measured with the Dutch version of the National Adult Reading Test (DART; Amsterdam) (Schmand et al., 1991), the vocabulary subscale of the Wechsler Adult

Intelligence Scale – Third Edition (WAIS-III; Barcelona) (Wechsler, 1997); the National Adult Reading Test (NART; Wollongong) (Nelson, 1982), and the Wechsler Abbreviated
Scale of Intelligence (WASI; Melbourne) (Wechsler, 1999).
b

Depressive symptoms measured with the Beck Depression Inventory (BDI; Amsterdam, Barcelona, Melbourne) (Beck et al., 1961) and Hamilton Depression Rating Scale

(HAMD; Wollongong) (Hamilton, 1960); and subsequently standardized to a z-score based on reported population means (Crawford et al., 2011; Zimmerman et al., 2004).
c

StDr/mth = standard drinks per month; Cig/mth = cigarettes smoked per month

d

ANCOVA on cannabis use level in cannabis users only, with right and left hemisphere OFC pattern as fixed factors, and the other two CB use levels as covariates.

Cumulative lifetime CB use of two users has been winsorised to reduce their influence (864,000 and 459,000 respectively replaced with 355,712 and 356,704, i.e., 3.00 and
3.01 standard deviations above the mean).
*p<.05
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OFC pattern type distribution across groups – HC vs. CB
χ tests of OFC pattern distribution between HC and CB users, indicated that both groups did
2

2

2

not differ significantly in right (χ (2) = 1.06, p = .59) or left (χ (2) = 0.30, p = .86) OFC pattern
distribution.

OFC pattern association with level of CB use
To discern the association between OFC pattern type and level of CB use, three separate
ANCOVAs were performed (i.e. one each for CB use levels – age of onset of regular use,
current monthly use, and cumulative lifetime use). As CB use levels were strongly correlated
(range of r = -.301 – .622, p < .001), the remaining two CB use levels were used as
covariates in all three ANCOVA analyses. For this analysis, six CB users (all males) were
excluded from the original sample due to missing CB use levels, resulting in a final sample of
140 CB users 1 . Cumulative lifetime CB use of two users was winsorised to reduce their

influence (864,000 and 459,000 respectively replaced with 355,712 and 356,704, i.e., 3.00
and 3.01 standard deviations above the mean). IQ and tobacco use, while differing between
HC and CB users, were not adopted as covariates, as they were not significantly related to
OFC pattern type (Table 2), nor did they affect the association between OFC pattern type and
level of CB use as covariates in the subsequent analysis.

ANCOVA with right and left OFC pattern as fixed factor show that the right OFC
pattern was significantly associated with cumulative lifetime use (Table 2; F2,133 = 3.91, p =
.022, ηp = .055) . After false discovery rate (FDR) correction (B-Y method (Benjamini and
2

2

Yekutieli, 2001), critical value = .02) the strength of this association was reduced to trendlevel. We observed that those CB users with right OFC Type III pattern had higher cumulative
lifetime use (M = 73,539, SD = 89,776) than those with Type I (M = 49,393, SD = 70,590, p =
.010, 95% CI [7314, 52249]) or Type II (M = 38,738, SD = 45,937, p = .039, 95% CI [1499,
57799]), controlling for age of onset of regular use and current monthly use (Fig. 2). We
therefore adopted cumulative lifetime CB use as a mediator in the subsequent mediation
model between OFC pattern type and depressive symptoms. No other significant association
was found.

1

The six excluded CB users did not differ in age (M = 26.33, SD = 11.91, n = 6; t(144) = 0.49, p = .62), IQ (M = 103.58, SD = 9.20, n = 5; t(141) = 0.00, p = 1.00), alcohol use (M =
22.40, SD = 18.08, n = 5; t(139) = 0.20, p = .85), and tobacco use (M = 92.00, SD = 141.19, n
= 4; t(140) = 1.43, p = .15) from non-excluded CB users. Nor did they differ significantly in
2
OFC sulcogyral pattern type distribution (n of Type I:II:III = 2:3:1, χ (2) = 3.13, p = .21; and n
2
of Type I:II:III = 3:1:2, χ (2) = 0.02, p = .99 for the right and left hemispheres respectively)
from the non-excluded CB users. However they did report lower depressive symptoms (M = .80, SD = 0.15, n = 6; t(142) = 2.27, p = .03) than non-excluded CB users.
2 ANCOVA with unwinsorised data suggest however that results no longer hold (F
2,133 = 2.22,
2
p = 0.11, ηp = .032).
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Fig. 2 Cumulative lifetime use in cannabis (CB) users by right orbitofrontal cortex (OFC)
pattern type, * p < .05. Error bars represent 95% confidence interval.

Lifetime CB use as mediator between OFC pattern and depressive symptoms
Given the higher incidence of depressive symptoms in our sample of CB users compared to
HC, and the OFC’s role in the manifestation of affective dysregulation in substance
dependence (Diekhof et al., 2008), we explored cumulative lifetime CB use as a mediator
between right OFC Type III pattern and depressive symptoms. The right OFC Type III pattern
was modeled as a categorical variable (i.e. presence versus absence of Type III). Covariates
included current monthly CB use and age of onset of regular use, which did and did not
significantly affect the model, respectively.

Within CB users, having a right OFC Type III pattern was not directly associated with
depressive symptoms. However, as shown in Fig. 3, right OFC Type III pattern was indirectly
associated with higher depressive symptoms, through greater amount of lifetime CB use (b =
3

0.14, 95% CI [0.04, 0.30]) . Given the significant difference between HC and CB users in IQ
and tobacco use level, we further conducted a second mediation analysis with lifetime CB
use, IQ, and tobacco use as joint mediators to rule out the influence of these confounders on
the model (Supplementary Figure 1). Both IQ and tobacco use were not significant mediators
of the model, and they did not significantly influence the association between right OFC Type
III, lifetime CB use, and depressive symptoms.

3

Mediation model remains valid and significant when re-analysed with unwinsorised data.
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Fig. 3 Cumulative lifetime cannabis (CB) use as mediator between right orbitofrontal cortex
(OFC) pattern type (categorical, Type III vs. non-Type III) and depressive symptoms in CB
users; indirect effect, b = 0.14, 95% CI = [0.04, 0.30].

Discussion
Our study was the first to investigate OFC sulcogyral pattern – largely determined by birth
(Chi et al., 1977) and measured via a validated classification method (Bartholomeusz et al.,
2013; Chiavaras and Petrides, 2000) – in relation to CB use, CB use levels and associated
depressive symptoms. We found no significant differences between the CB and HC groups,
in contrast with our first hypothesis. However, those CB users with right OFC Type III pattern
(relative to Type I and II) had higher cumulative lifetime CB use; and cumulative use in turn
mediated an indirect association between right OFC Type III pattern and higher depressive
symptoms. Our findings support the hypothesis that specific OFC gyrification patterns (i.e.
Type III pattern) are associated with greater lifetime cannabis use, and are furthermore
consistent with previous studies demonstrating greater CB use to be associated with higher
depressive symptoms (Crane et al., 2015). In sum, OFC pattern type did not contribute to the
risk of becoming a CB user, but had an impact on individuals who became CB users, by
predisposing them to greater levels of use throughout their lifetime. These users with greater
levels of lifetime CB use may subsequently experience greater depressive symptoms.

Our findings suggest that Type III pattern in the right hemisphere may predispose
individuals to greater levels of CB use. This may occur via the altered emotional and cognitive
features associated with Type III pattern – such as poor regulatory control, including higher
negative emotionality, impulsivity, and stress reactivity (Nakamura et al., 2007; Whittle et al.,
2014). The OFC function is relevant to regulatory control as it is involved in monitoring and
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processing motivational information, therefore supporting context-appropriate behaviour
(Diekhof et al., 2008; Kringelbach and Rolls, 2004; Tremblay and Schultz, 1999). Impaired
regulatory function of the OFC could thus manifest as a maladaptively intense drive to
procure substances, facilitating greater and more compulsive substance-seeking (Volkow and
Fowler, 2000). Indeed, the temperamental variables linked to Type III pattern (e.g. higher
negative emotionality, impulsivity, stress reactivity, and sensation-seeking (Nakamura et al.,
2007; Whittle et al., 2014)) have been associated with CB use – increased use frequency and
risk of lifetime use (Creemers et al., 2010, 2009). Nevertheless, future studies will be
necessary to substantiate the link between OFC neuroanatomy, temperamental variables of
behaviour regulation, and substance use.

In our exploratory analyses, we further showed that higher lifetime CB use is
associated with higher depressive symptoms, thus mediating an indirect association between
Type III pattern and greater depressive symptoms. This is consistent with previous evidence
linking heavy CB use and depressive symptoms (Crane et al., 2015) or risk of developing
depressive disorders (Lev-Ran et al., 2014). We suggest that the Type III pattern may reflect
poor regulatory control, which underlies the greater level of CB use, and in turn higher CBuse-related depressive symptoms in users. In substantiation of our claim, CB use and greater
depressive symptoms have been demonstrated to co-occur in adolescents with low levels of
self-control (Otten et al., 2010). Additionally in a study of abstinent substance-dependent
users, measures of self-regulation and emotional functioning were directly correlated
(Verdejo-García et al., 2007), suggesting regulatory control to be relevant to the manifestation
of emotional disturbances such as depressive symptoms. Unfortunately, as we do not have a
direct measure of ‘regulatory control’, we are unable to examine the contribution of this trait
behaviour in both OFC pattern and related psychopathologies. Our findings contrast
previously reported association between right OFC Type I pattern (not Type III) and higher
depressive symptoms in a community sample of non-CB-using adolescents (Whittle et al.,
2014). This may reflect the specific interaction between CB use and pattern type on emerging
depressive symptoms, with higher depressive symptoms in CB users with OFC Type III
pattern manifesting as a result of prolonged high levels of use. However in our sample of
HCs, we did not find any association between OFC pattern type and depressive symptoms
either (analysis not shown, p = .67 and p = .77 for left and right hemisphere respectively). We
speculate our lack of finding to be due to the age difference between our adult sample and
Whittle and colleague’s (2014) adolescent sample, as emotional regulation may develop with
age (McRae et al., 2012).

It is noteworthy that the association we found between lifetime CB use and OFC
pattern was confined to the right hemisphere. The right hemisphere is suggested to be
specialised for socioemotional functioning and emotion management (Borod 1992; Schore
2001; Tranel et al. 2002). Greater right over left frontal activation has also been linked to
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greater negative affective response and difficulties with affective regulation, that may be
related to both internalising (e.g. anxious behavior) and externalising (e.g. aggressive
behaviour) problems (Wheeler et al. 1993; Fox et al. 1996). An overwhelming percentage of
studies investigating OFC pattern type have found evidence linking pattern Type III and
psychopathology in the right hemisphere (Chakirova et al. 2010; Takayanagi et al. 2010;
Bartholomeusz et al. 2013). Overall, our study along with the examples above contribute to
evidence of the lateralisation of OFC function (Happaney et al. 2004), possibly related to
asymmetry in the timeline and functional specialization of cortical development (Toga &
Thompson 2003).

The OFC classification method used in this study is both valid and reliable, and
minimally affected by confounders including gender differences and imaging sites. In support
of the reliability of our OFC classification, the percentage distribution of OFC pattern found in
our sample (Type I:II:III = 49:19:32%) was similar to that of previously examined samples of
healthy controls (aggregated means of Type I:II:III = 60:19:20%; χ (2) = 4.32, p = .12)
2

(Bartholomeusz et al., 2013; Chakirova et al., 2010; Chiavaras and Petrides, 2000; Cropley et
al., 2015; Ganella et al., 2015; Isomura et al., 2017; Lavoie et al., 2014; Nakamura et al.,
2007; Nishikawa et al., 2015; Takahashi et al., 2014, 2015; Takayanagi et al., 2010; UeharaAoyama et al., 2011; Watanabe et al., 2014; Whittle et al., 2014). We also did not find any
gender-related differences in OFC pattern distribution, consistent with most previous studies
(Uehara-Aoyama et al., 2011; Whittle et al., 2014). Finally, we did not observe any imaging
site related differences, which points to the reliability of OFC pattern classification across
different scanners in our sample. While there is no single conclusive study on the stability of
the OFC pattern across countries and population, it nevertheless appears to be a potentially
stable morphological trait marker, useful for understanding temperament, behaviour, and
psychopathology.

We acknowledge some limitations of our study. Firstly, while we propose selfregulatory deficits related to OFC Type III pattern to predispose CB users to greater levels of
use, we did not have measures of behavioural self-regulation. As such, we were unable to
examine the relationship between behavioural regulation and OFC pattern type. This may
represent a possible future avenue for investigation. Second, depressive symptoms were only
assessed cross-sectionally at the time of assessment. Therefore we cannot discern to what
extent depressive symptoms precipitated CB use, and whether OFC pattern may have
informed depressive symptoms prior to CB initiation. We also did not examine other
measures of affective disturbances such as anxiety, in relation to CB use.

We adopted

depressive (rather than anxiety) symptoms as an index of affective disturbance due to the link
between CB use and subsequent depressive symptoms (Degenhardt et al., 2003), and on
grounds of anxiety symptoms possibly precipitating rather than being a consequence of CB
use (Stapinski et al., 2016). Furthermore, not all imaging sites collected information on
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anxiety symptoms. Future longitudinal studies will be necessary to fully explore whether OFC
pattern is associated with differences in depressive and anxiety symptoms prior to CB use, or
whether such outcomes arose as a result of continual CB exposure. Additionally, as genetic
factors may affect cortical folding patterns (Atkinson et al., 2015), genetic or epigenetic
factors guiding early neurodevelopment may present as more robust biomarkers of CB use
level (Agrawal and Lynskey, 2006; Ystrom et al., 2014), as compared to OFC sulcogyral
pattern. Multifactorial models integrating genetic, neurobiological, and behavioural factors will
be necessary to provide a more complete account of the causal influences on CB use.
Finally, we did not find any association between OFC pattern and alcohol or tobacco use. The
specificity of the association between OFC pattern and greater lifetime CB use, rather than
other substance (alcohol and tobacco) use may be due to the fact that alcohol and tobacco
use were quantified as ‘monthly use’ in our study, rather than ‘cumulative use’. Indeed, we
also found no association with current monthly CB use. Given that short-term measures of
use (i.e. monthly, compared to lifetime use) may fluctuate with situational changes, these may
be less reliably associated with stable trait markers such as OFC pattern. However, further
clarification in users of other substances (e.g. alcohol, tobacco) will be necessary.

Conclusion
In conclusion, while there was no particular OFC pattern Type that conferred risk for CB use
versus non-use, OFC Type III pattern in the right hemisphere was associated with greater
lifetime use in CB users. Greater lifetime CB use was in turn associated with greater
depressive symptoms in CB users. Future longitudinal work is needed to ascertain the extent
to which OFC pattern informs pre-existing temperamental features that may contribute
towards substance use. Meanwhile, comprehensive examination and integration of various
factors including genetic, ethnic, and prenatal factors might provide insight regarding the
moderators of OFC pattern distribution across populations. This may in turn support the use
of OFC pattern type as a stable trait marker to further understand pre-existing vulnerabilities
that influence substance use level among CB and/or other substance users, and mental
health problems, in general or specifically associated with substance use.
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